Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
305.00    0.00 (0.00%)
Bid:
300.00
Ask:
310.00
Spread: 10.00 (3.333%)
Market Cap: £38.70m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Director's Dealings

13 Jan 2009 10:41

RNS Number : 5360L
BrainJuicer Group PLC
13 January 2009
 



Press Release

 13 January 2008

BrainJuicer Group PLC

('BrainJuicer' or 'the Company')

Director's Dealings

BrainJuicer Group PLC, (AIM: BJU), a leading international online market research agency, was informed on 13 January 2009 that on the same day, Simon Godfreya non-executive director of the Company, exercised 84,298 options over ordinary shares of 1p each in the Company ('Ordinary Shares') at a price of 11.4p per Ordinary Share, pursuant to the Company's Employee Share Option Scheme.

Following this transaction, Mr Godfrey is interested in 84,298 Ordinary Shares, representing 0.65% of the total issued share capital of the Company. These shares will rank pari passu with all existing Ordinary Shares.

Following this notification, the Company has 12,929,634 Ordinary Shares in issue.

 

- Ends -

 For further information, please contact:

BrainJuicer plc

John Kearon, Chief Executive Officer

Tel: +44 (0)20 7043 1000 

James Geddes, Chief Financial Officer

www.brainjuicer.com

Canaccord Adams Limited

Mark Williams / Adria Da Breo Richards

Tel: +44 (0)20 7050 6500

www.canaccordadams.com

UK media enquiries:

Abchurch Communications

Tel: +44 (0) 20 7398 7700

Heather Salmond / Jack Ballantyne

Tel: +44 (0) 20 7398 7714

jack.ballantyne@abchurch-group.com

www.abchurch-group.com 

Notes to Editors

BrainJuicer carries out quantitative online research using innovative, bespoke software to produce insightful market research for large, multinational companies, including 15 of the world's top 100 companies (FT 500 September 2006).

BrainJuicer operates in a growing sector of the US$25bn global research market, namely quantitative online research. BrainJuicer's main competitors are large traditional market research providers who have dominated the market for off-line market research, such as AC Nielsen, Millward Brown, Research International and Taylor Nelson Sofres.

Whilst the largest traditional research companies have developed their own online capability, BrainJuicer has a number of key attributes which have contributed to it achieving rapid growth and winning contracts with prestigious clients, including:

• Research platform that delivers greater diagnostic insight. BrainJuicer has developed tools and award-winning techniques that enable it to provide a greater level of qualitative diagnostic insight into quantitative market research. These techniques enable clients to enhance their understanding of consumer preference and help them make decisions on the best way to develop their products and services.

• Speed. BrainJuicer's automated research techniques enable it to conduct complicated studies very quickly. BrainJuicer's rapid deployment and results production, even on multi-country studies, provide clients with a speed to market advantage in the development of new products and services.

• A scaleable online-only business model. Unlike the traditional research companies who maintain both on and offline data collection capabilities, BrainJuicer is able to focus on operating a scaleable online-only business model.

To date the Group has conducted projects in over 50 countries and more than 30 languages and has established offices in the UK, the Netherlands and the US.

The Group's revenues come from full service market research work, and from its online Juicy Brains Panel in the UK.

Further information on BrainJuicer can be found at www.brainjuicer.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBGGDBIXBGGCX
Date   Source Headline
8th Jul 20264:15 pmRNSDividend Timetable
8th Jul 20267:00 amRNSFinal Results
2nd Jul 20267:00 amRNSNotice of Investor Presentation
1st May 20264:30 pmRNSHolding(s) in Company
21st Apr 20267:01 amRNSRelationship Agreement with Brave Bison
21st Apr 20267:00 amRNSQ4 and Full Year Trading Update
9th Apr 20267:00 amRNS-RLaunch of next evolution of Test Your Ad platform
30th Mar 20264:30 pmRNSHolding(s) in Company
30th Mar 20263:30 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTrading Update
16th Mar 20267:00 amRNSTrading Update
5th Mar 20263:15 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:15 pmRNSHolding(s) in Company
3rd Mar 20264:06 pmRNSBoard Change
2nd Mar 20261:39 pmRNSShareholder update & PDMR Dealing
2nd Mar 20267:00 amRNSDirectorate change
30th Jan 20261:00 pmRNSBoard Committee and Change of Role Update
20th Jan 20267:00 amRNSTrading Update
12th Jan 20264:45 pmRNSAppointment of Joint Corporate Broker
2nd Dec 20257:00 amRNSInterim Results
20th Nov 202511:45 amRNSHolding(s) in Company
24th Oct 20253:28 pmRNSHolding(s) in Company
22nd Oct 20257:00 amRNSTrading Update
14th Oct 20259:16 amRNSCapital Markets Day
6th Oct 20253:30 pmRNSDirector/PDMR Shareholding
30th Sep 20257:00 amRNSDirector/PDMR Shareholding - replacement
29th Sep 20255:48 pmRNSDirector/PDMR Shareholding
29th Sep 20251:27 pmRNSHolding(s) in Company
26th Sep 20252:29 pmRNSHolding(s) in Company
26th Sep 20257:00 amRNSDirector/PDMR Shareholding
24th Sep 20253:01 pmRNSResult of AGM
23rd Sep 20257:00 amRNSTrading Update
15th Sep 20251:00 pmRNSDirector/PDMR Shareholding
27th Aug 20254:51 pmRNSNotice of AGM
8th Aug 20254:35 pmRNSDirector/PDMR Shareholding
9th Jul 20257:00 amRNSDirector Role Change
9th Jul 20257:00 amRNSFinal Results
9th Jul 20257:00 amRNSTrading Update
4th Jul 202511:45 amRNSHolding(s) in Company
4th Jul 20257:00 amRNSHolding(s) in Company
16th Jun 20251:30 pmRNSHolding(s) in Company
14th May 20257:00 amRNSEstablishment of New Long-Term Incentive Plan
24th Apr 20251:53 pmRNSHolding(s) in Company
23rd Apr 20257:00 amRNSTrading Statement
23rd Jan 20257:00 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTrading Update
8th Jan 202510:15 amRNSHolding(s) in Company
3rd Dec 20247:00 amRNSInterim Results
28th Nov 20247:00 amRNSInterim Results Presentation
21st Nov 20243:31 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.